The resampling of the tumour can be considered if there are discrepancies between the mutation results from the biopsy and CT findings (based on deep learning, radiomics, and semantic markers); these combined analyses can potentially reduce the chances of missing EGFR mutations in a tumour mass. The gene discussed is EGFR; the disease is neoplasm.